We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The injectable drug is approved for treatment of certain patients with metastatic ovarian cancer, small-cell lung cancer and recurrent or persistent cervical cancer. Read More
Clinicians can use the software to securely exchange documents, such as lab results, with transplant patients and can offer personalized advice. Read More
Biogen said it plans to price the monthly infusion at $4,312 or $56,000 annually, a price that many critics say will quickly bankrupt Medicare. Read More